2020
Overview
Recombinant vaccines are vaccines produced using recombinant DNA technology, in which genes encoding specific antigens from a pathogen are inserted into host cells or organisms that then manufacture those antigens. Rather than using whole live or inactivated pathogens, these vaccines present purified proteins or antigenic components to the immune system, an approach that can improve safety and allow precise targeting of the immune response. Recombinant techniques underpin vaccines against a range of diseases and have become central to modern vaccine development, including subunit and protein-based formulations. Research in the journal touches on vaccine development relevant to this approach; for example, one study characterizes the Abdala vaccine, a recombinant protein-based COVID-19 vaccine, while other work explores antigen-delivery and adjuvant strategies, such as a nanoadjuvant developed for vaccination against tuberculosis, and broader discussions of COVID-19 vaccine development, prospects, and challenges. These investigations reflect ongoing efforts to design and evaluate vaccines that elicit effective and durable immune protection. This page brings together peer-reviewed, open-access research relevant to recombinant vaccines and the wider field of vaccine design, antigen delivery, and immunization against viral and other infectious diseases.
Research published in this journal
6 peer-reviewed articles, ranked by relevance. Each links to its DOI.
2020
2014
2021
2017
2025
How this research is being cited
The 6 articles above have been cited 5 times in the scholarly literature. Citation data via OpenAlex and Crossref, updated Jun 2026.
-
2023 · Elsevier eBooks
-
2020 · Eurasian journal of veterinary sciences
-
2020 · Jurnal Ilmu Administrasi Media Pengembangan Ilmu dan Praktek Administrasi
-
2020 · Jurnal Ilmu Administrasi: Media Pengembangan Ilmu dan Praktek Administrasi
A sample of recent works citing this journal's research on Recombinant Vaccines, linking to each citing work.